FDA codifies infant oxygen monitor controls covering performance, caregiver understanding and instructions about their limits
An October 9 FDA order puts controls for over-the-counter infant pulse and oxygen monitors into federal regulations. It codifies a classification that applied in November 2023, rather than announcing a new product approval. The controls require testing across expected users and conditions, including skin pigmentation, and instructions that help caregivers interpret readings and understand appropriate actions.
- Why it matters
- Safety requirements include whether caregivers can interpret the output and understand what action to take, alongside testing of the sensor and software.
- What to watch
- The published order is effective October 9, 2026. Its labeling and performance controls concern an intended use; it does not authorize claims to prevent sudden infant death.
The limit. No device was tested or advertisement audited. A category's special controls are not a finding that every product sold meets them.
How this record was read
Read October 9 Arizona time. Retained and read the published Federal Register full text, GovInfo HTML, three-page PDF with extracted text, and Federal Register API metadata for document 2026-20726. Limits: the underlying De Novo submission, original 2023 decision, individual product labeling and performance data were not read. The order codifies an existing classification and provides no comparative recommendation or finding that every infant monitor satisfies these controls.
